An autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are genetically engineered to express an anti-CD19 CAR; upon engagement of CD19 on B-lineage malignant cells, the CAR T cells activate and mediate cytotoxicity, leading to elimination of CD19+ tumor cells and on-target B-cell depletion. Administered as a single IV infusion (0.5–6×10^6 cells/kg).